United States· US:23155-977_cef2c469-9a1b-46f3-b08f-57ea2876311f

nisoldipine

A nisoldipine product containing nisoldipine, registered in United States by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.. The same ATC class is registered in 4 of our 19 countries.

ATC C08CA07

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisednisoldipineATCC08CA07REGISTER NO.US:23155-977_cef2c469…PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Nisoldipine is registered in 4 of 19 countries.

Countries holding a registration under ATC C08CA07 (nisoldipine), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 3 of them publish a price we can compare per daily dose

Nisoldipine · ATC C08CA07

4 / 19 countries

  • Belgiumprice
  • Finlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
NISOLDIPINE
Manufacturer
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Country
United States (US)
ATC code
C08CA07
ATC class
Nisoldipine
Defined daily dose
20 mg, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 1

  • ndc11
    23155-977-01

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

230 interactions on record for nisoldipine.

Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Nisoldipine · interactions on record

230 records

  • 10 severe
  • 168 moderate
  • 5 minor
  • 46 info

Most severe, free to view

  • DolasetronA04AA04severe
  • KetoconazoleH02CA03severe
  • KetoconazoleJ02AB02severe
  • CeritinibL01ED02severe

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nisoldipine in 3 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nisoldipine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0c943337-d428-4118-bbcb-be8ae7776404
GET /v1/drugs/0c943337-d428-4118-bbcb-be8ae7776404?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "17",
  "substance": "NISOLDIPINE",
  "productndc": "23155-977",
  "dosage_form": "TABLET, FILM COATED, EXTENDED RELEASE",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "ANDA216606",
  "marketing_category": "ANDA"
}

See everything about nisoldipine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.